Abstract:Although, by age 40, individuals with Down syndrome (DS) develop amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) linked to cognitive impairment in Alzheimer’s disease (AD), not all people with DS develop dementia. Whether Aβ plaques and NFTs are associated with individuals with DS with (DSD +) and without dementia (DSD −) is under-investigated. Here, we applied quantitative immunocytochemistry and fluorescent procedures to characterize NFT pathology using antibodies specific for tau phosphorylation (pS422, AT8), truncation (TauC3, MN423), and conformational (Alz50, MC1) epitopes, as well as Aβ and its precursor protein (APP) to frontal cortex (FC) and striatal tissue from DSD + to DSD − cases. Expression profiling of single pS422 labeled FC layer V and VI neurons was also determined using laser capture microdissection and custom-designed microarray analysis. Analysis revealed that cortical and striatal Aβ plaque burdens were similar in DSD + and DSD − cases. In both groups, most FC plaques were neuritic, while striatal plaques were diffuse. By contrast, FC AT8-positive NFTs and neuropil thread densities were significantly greater in DSD + compared to DSD −, while striatal NFT densities were similar between groups. FC pS422-positive and TauC3 NFT densities were significantly greater than Alz50-labeled NFTs in DSD + , but not DSD − cases. Putaminal, but not caudate pS422-positive NFT density, was significantly greater than TauC3-positive NFTs. In the FC, AT8 + pS422 + Alz50, TauC3 + pS422 + Alz50, pS422 + Alz50, and TauC3 + pS422 positive NFTs were more frequent in DSD + compared to DSD- cases. Single gene-array profiling of FC pS422 positive neurons revealed downregulation of 63 of a total of 864 transcripts related to Aβ/tau biology, glutamatergic, cholinergic, and monoaminergic metabolism, intracellular signaling, cell homeostasis, and cell death in DSD + compared DSD − cases. These observations suggest that abnormal tau aggregation plays a critical role in the development of dementia in DS.

Untangle the mystery behind DS-associated AD - Is APP the main protagonist?

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

A Common Link Between Alzheimer's Disease and Down Syndrome

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein

Common genetic signatures of Alzheimer's disease in Down Syndrome

A Novel Mechanism Underlying Pathogenesis of Down Syndrome

Alzheimer’s drugs, APPlication for Down syndrome?

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration.

Amyloid-β Precursor Protein Facilitates the Regulator of Calcineurin 1-Mediated Apoptosis by Downregulating Proteasome Subunit Α Type-5 and Proteasome Subunit Β Type-7.

The amyloid precursor protein: beyond amyloid

APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons

Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.

The mediating role of plasma glial fibrillary acidic protein in amyloid and tau pathology in Down's syndrome

P4-064 Increased BACE1 Maturation in Down Syndrome

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

Frontal Cortex and Striatal Cellular and Molecular Pathobiology in Individuals with Down Syndrome with and Without Dementia

The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome

Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses